Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MYOC | Q99972 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568018 | 0.83 | NLRP3 (0.55) | NPSR1ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL4442403 | 0.82 | ALDH1A1 (0.39) | MEN1KMT2AMAPTNPSR1MYOC | |
| SCHEMBL18511360 | 0.82 | LMNA (0.43) | NPSR1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL978540 | 0.81 | NPC1 (0.56) | MAPTALDH1A1GAA | |
| SCHEMBL20865561 | 0.80 | ALDH1A1 (0.56) | MEN1KMT2AMAPTNPSR1ALDH1A1 | |
| SCHEMBL13636106 | 0.80 | CYP3A4 (0.45) | NPSR1ALDH1A1GAAMAPK1 | |
| SCHEMBL31470226 | 0.80 | CYP3A4 (0.45) | NPSR1ALDH1A1GAAMAPK1 | |
| SCHEMBL8478429 | 0.80 | RXFP1 (0.41) | MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL26796257 | 0.80 | MEN1 (0.48) | MEN1KMT2AALDH1A1GAA | |
| SCHEMBL21568091 | 0.79 | MEN1 (0.58) | MEN1KMT2AMAPTNPSR1MYOC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | MEN1 2993/4885KMT2A 2056/4885MAPT 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.